A Phase 2, Multicentre, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
This is an open-label, multicentre study to confirm the safety and efficacy of durvalumab +
daratumumab (D2) in subjects with relapsed and refractory multiple myeloma. This study will
also explore the safety and efficacy of the addition of pomalidomide + dexamethasone to
durvalumab + daratumumab (PD3).
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society